<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363583</url>
  </required_header>
  <id_info>
    <org_study_id>151:633=01</org_study_id>
    <nct_id>NCT01363583</nct_id>
  </id_info>
  <brief_title>Study on the Effect of Prostacyclin Compared to Placebo in Traumatic Brain Injury</brief_title>
  <official_title>Prostacyclin Treatment in Severe Traumatic Brain Injury: a Microdialysis and Outcome Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective consecutive double-blinded randomized study on the effect of
      PGI2, prostacyclin (epoprostenol, Flolan®) versus placebo (saline)in patients with severe
      traumatic brain injury. All patients with severe traumatic brain injury were eligible for
      inclusion. Inclusion criteria: verified traumatic brain injury, Glasgow Coma Score (GCS) at
      intubation and sedation of ≤ 8, age 15-70 years, a first-recorded cerebral perfusion pressure
      (CPP) of &gt; 10 mm Hg, and arrival within 24 hours after trauma.

      Tne primary aim was to evaluate whether treatment with epoprostenol would reduce a
      lactate/pyruvate ratio,as measured by cerebral microdialysis after 24 hours of treatment.

      A secondary aim was to evaluate the effect of epoprostenol on systemic inflammatory markers,
      measured by different cytokines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactate/pyruvate ratio 24 hours after start of epoprostenol versus placebo</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of systemic inflammatory markers</measure>
    <time_frame>4 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>epoprostenol, Flolan®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Measurement on the effect of epoprostenol on lactate/pyruvate ratio measured by cerebral microdialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Effect of saline on the lactate/pyruvate ratio measured by cerebral microdialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epoprostenol versus normal saline</intervention_name>
    <description>0.5 ng/kilogram/minute during 4 days</description>
    <arm_group_label>epoprostenol, Flolan®</arm_group_label>
    <arm_group_label>normal saline</arm_group_label>
    <other_name>Flolan®</other_name>
    <other_name>Normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>0.5-1.5 ml/hour during 4 days</description>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  traumatic brain injury, Glasgow coma scale ≤ 8

        Exclusion Criteria:

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars-Owe Koskinen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umea university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Umea university</name>
      <address>
        <city>Umea</city>
        <zip>90187</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Olivecrona M, Rodling-Wahlström M, Naredi S, Koskinen LO. Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study. J Neurotrauma. 2009 Aug;26(8):1251-62. doi: 10.1089/neu.2008-0605.</citation>
    <PMID>19226191</PMID>
  </results_reference>
  <verification_date>September 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>May 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <last_update_submitted>May 27, 2011</last_update_submitted>
  <last_update_submitted_qc>May 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Lars-Owe Koskine</name_title>
    <organization>Umea university</organization>
  </responsible_party>
  <keyword>traumatic brain injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

